Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022

Presentation will Showcase Trial Design in Upcoming Phase 3 Trial in Parkinson's Disease

Berwyn, Pennsylvania--(Newsfile Corp. - March 8, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the Company will be presenting at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD™ 2022). The hybrid conference will be hosted in-person in Barcelona, Spain, and virtually from March 15-20, 2022.

Maria L. Maccecchini, Ph.D., Founder, President, and CEO, and Cheng Fang, Ph.D., Senior Vice President of Research & Development, will participate in-person.

The presentation will showcase endpoints and trial design of the Company's upcoming Phase 3 clinical studies of Buntanetap (previously known as Posiphen or ANVS401) for the treatment of Parkinson's Disease (PD).

Presentation Details:
Title: Positive clinical outcomes of Posiphen in two Phase 2a studies - Alzheimer's Disease and Parkinson's Disease
Abstract: SO394 / #308
Session: ABeta and other targeting therapies in AD
Time: March 20, from 9:05-11:05 a.m. C.E.T. / 3:05-5:05 a.m. E.T.
Presenter: Maria L. Maccecchini, Ph.D., Founder, CEO and President, Annovis Bio

About Annovis Bio, Inc.

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD), and other chronic neurodegenerative diseases, including Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD, and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. Annovis conducted two Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/PD study Buntanetap showed improvement in memory loss and dementia associated with AD, as well as body and brain function in PD.

For more information on Annovis Bio, please visit the Company's website and follow us on LinkedIn and Twitter.

Forward-Looking Statements

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of Buntanetap clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.


Media and Investor Contact:
Nic Johnson
Russo Partners, LLC
(303) 482-6405

To view the source version of this press release, please visit

Back to news